Ranolazine hydrochloride slow-release preparation and its preparing method

A technology for ranolazine hydrochloride and sustained-release preparations, which is applied in the field of oral sustained-release preparations containing ranolazine hydrochloride and its preparation, and can solve problems such as incomplete absorption, incomplete release of ranolazine base, and inability to sustain cardiac protection.

Active Publication Date: 2007-01-10
QILU PHARMA HAINAN
View PDF2 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Since ranolazine base is slightly to very slightly soluble in intestinal fluid, and the patent fails to provide conclusive data demonstrating that the pH-dependent adhesive facilitates release of ranolazine base in the intestinal tract, release of ranolazine base may be incomplete leading to incomplete incomplete a...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ranolazine hydrochloride slow-release preparation and its preparing method
  • Ranolazine hydrochloride slow-release preparation and its preparing method
  • Ranolazine hydrochloride slow-release preparation and its preparing method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0093] Ranolazine Hydrochloride Sustained Release Tablets Formula:

[0094] Each 1000 tablets of Ranolazine Hydrochloride Sustained Release Tablets contains

[0095] Ranolazine Hydrochloride 600g

[0096] Hydroxypropyl Methyl Cellulose (HPMC K100M CR) 78g

[0097] Ethylcellulose (EC 10CP STD.PREM.FP) 39

[0098] Eudragit  RS PO 46.8g

[0099] Magnesium stearate 15.6g

[0100] 85% ethanol aqueous solution appropriate amount

[0101] (1) Pass the formulated amount of hydroxypropyl methylcellulose and ethyl cellulose through a 40-mesh sieve 5 times and mix thoroughly.

[0102] (2) Mix ranolazine hydrochloride with the materials in (1) in equal increments, pass through a 40-mesh sieve 5 times and fully mix.

[0103] (3) Add an appropriate amount of 85% ethanol aqueous solution to the uniformly mixed material, mix uniformly, make a soft material, pass through a 20-mesh sieve to granulate, and dry at 40-50° C. for 2 hours.

[0104] (4) Add the prescribed amount of magnesium...

Embodiment 2

[0107] As described in Example 1, except that hydroxypropyl methylcellulose HPMC K100M CR was replaced by hydroxypropyl methylcellulose HPMC K4M CR, Eudragit  The amount of RS PO was increased to 60g, ethylcellulose EC 10CP STD.PREM.FP was replaced with ethylcellulose EC 100CPSTD.PREM.FP and the amount was reduced to 25.8g.

Embodiment 3

[0109] As described in Example 1, the difference is that the amount of hydroxypropylmethyl cellulose (HPMC K100M CR) is increased to 90g, and Eudragit  RL PO instead of Eudragit  For RS PO, the amount of ethyl cellulose was reduced to 27g.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Viscosityaaaaaaaaaa
Diameteraaaaaaaaaa
Login to view more

Abstract

The present invention relates to a ranolazine hydrochloride delayed-release preparation and its preparation method. Said ranolazine hydrochloride delayed-release preparation contains 25-95 wt% of ranolazine hydrochloride and one or several kind of medicinal inert auxiliary materials, including delayed-release matrix, adhesive, disintegrating agent, diluent, lubricating agent, flow aid or moistening agent.

Description

(1) Technical field [0001] The invention relates to a sustained-release preparation of ranolazine hydrochloride and a preparation method thereof, in particular to an oral sustained-release preparation containing ranolazine hydrochloride and a preparation method thereof. (2) Background technology [0002] Ranolazine hydrochloride is N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazinyl}acetamide disalt salt. U.S. Patent No. 4,567,264 discloses ranolazine (±)-N-(2,6-dimethylphenyl)-4-[2-hydroxyl-3-(2-methoxyphenoxy)-propyl]-1 - piperazine acetamide and pharmaceutically acceptable salts thereof, and discloses their use for the treatment of cardiovascular diseases including arrhythmia, variability and exercise angina, and myocardial infarction. [0003] U.S. Patent No. 5,506,229 discloses the use of ranolazine and pharmaceutically acceptable salts and esters thereof for the treatment of physically or chemically damaged tissues, including cardioplegia, h...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/495A61P9/10
Inventor 张宇红杨清敏于艳玲唐玮李颖
Owner QILU PHARMA HAINAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap